BERINERT addresses the problem of C1-INH deficiency by replacing missing or dysfunctional C1-INH
Mean C1-INH activity over time in 23 patients2
In a prospective, randomized, open-label, crossover study, 23 subjects with mild or moderate HAE received a single dose of BERINERT (1000 units) IV or SC during an attack-free interval.2
References: 1. Fay A, Abinun M. Current management of hereditary angio-oedema (C’1 esterase inhibitor deficiency). J Clin Pathol. 2002;55(4):266-270.
2. Martinez-Saguer I, Cicardi M, Suffritti C, et al. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Transfusion.
|Adults (n=35)||Children (n=5)‡|
|AUC(0-t) (hr x IU/mL)†||12.8||9.78|
|Volume at steady state (mL/kg)||35.4||38.8|
|Mean residence time (hr)||26.4||24.0|